ERBB2 and breast carcinoma: In order to achieve targeted delivery of siPlk1 to Her2+ breast cancer, Dou et al. designed an anti-Her2 single-chain variable fragment antibody (ScFv Her2)-decorated PEG–PLA-based nanoparticles encapsulated with siPlk1 (ScFv Her2 -NP si Plk1).